Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Pens Pharmacogenomics Deal With J&J Company to Predict Drug Response

NEW YORK, Jan. 11 (GenomeWeb News) - Perlegen Sciences will genotype patients for Johnson & Johnson Pharmaceutical Research and Development to find genetic markers indicating response to an undisclosed drug, the company said today.

 

Under the agreement, Perlegen will determine SNPs in several hundred patients and correlate them with therapeutic response to the drug. The aim is to predict the patient population that responds best to the agent.

 

The two parties did not disclose the terms of the collaboration. J&JPRD is a Johnson & Johnson company.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.